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Human Ataxin-2 (ATXN2) gene locus variants have been associated with obesity, diabetes 
mellitus type 1 and hypertension in genome-wide association studies, while mouse studies 
showed the knock-out of Atxn2 to lead to obesity, insulin resistance and dyslipidemia. 
Intriguingly, the deficiency of ATXN2 protein orthologues in yeast and flies rescues the 
neurodegeneration process triggered by TDP-43 and Ataxin-1 toxicity. To understand the 
molecular effects of ATXN2 deficiency by unbiased approaches, we quantified the global 
proteome and metabolome of Atxn2-knock-out mice with label-free mass spectrometry. In liver 
tissue, significant downregulations of the proteins ACADS, ALDH6A1, ALDH7A1, IVD, MCCC2, 
PCCA, OTC, together with bioinformatic enrichment of downregulated pathways for branched 
chain and other amino acid metabolism, fatty acids and citric acid cycle were observed. 
Statistical trends in the cerebellar proteome and in the metabolomic profiles supported these 
findings. They are in good agreement with recent claims that PBP1, the yeast orthologue of 
ATXN2, sequestrates the nutrient sensor TORC1 in periods of cell stress. Overall, ATXN2 
appears to modulate nutrition and metabolism, and its activity changes are determinants of 




Ataxin-2 (ATXN2) is a stress-regulated protein of 124 kDa size, which is expressed in 
specific neuron populations, but also in hepatocytes (1-4). The structure of the human ATXN2 
protein is characterized (1) by the N-terminal polyQ domain (5), (2) by dispersed proline-rich-
domains that mediate association with various SH3-motif containing proteins of the tyrosine 
kinase receptor endocytosis machinery and thus modulate neuro-trophic signaling (6, 7), (3) by 
a C-terminal PAM2 motif that mediates interaction with the poly(A)-binding protein PABPC1 that 
is crucial for mRNA translation (8) and (4) by Lsm and Lsm-AD sequences that mediate the 
association with RNAs (9-11). ATXN2 is normally localized at the rough endoplasmic reticulum 
(12), but it relocalizes during periods of low cell energy together with PABPC1 to stress granules 
where the quality control of RNA occurs (3) and where fasting responses are modulated (13). 
The suppression of Ataxin-2 in mice and flies modulates mRNA translation and circadian clock 
(4, 14-16). 
In human populations, several independent genome wide association studies (GWAS) 
have underlined the importance of variants at the genomic locus of ATXN2. They influence the 
risk for obesity, type 1 diabetes, hypertension and cardiovascular infarction (17-26). Their 
impact is strong enough to stand out as genetic modifiers of human longevity (27, 28). Whether 
additive effects of co-regulated neighbor genes at this locus play a causal role, has been 
discussed in a recent review (29).  
In mice, two independent Atxn2-knock-out (KO) lines confirmed phenotypes of obesity 
(30, 31), with excessive liver fat and glycogen deposits, insulin resistance and dyslipidemia also 
being noted by the age of 6 months. Thus, even in the absence of high-fat-diet and within the 
short lifespan of rodents, the monogenic deficiency of Ataxin-2 is sufficient to trigger important 
features of the human metabolic syndrome.  
Conversely, the overactivity of Ataxin-2 due to polyglutamine (polyQ) expansions 
encoded by unstable (CAG)-repeat expansions in the human ATXN2 gene results in cell 
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atrophy of specific neuronal populations. The polyQ-expansion of ATXN2 leads to a process of 
protein insolubility and aggregate formation with insidious toxicity throughout the nervous 
system, depending on the expansion size and polygenic interactions, possibly also on CAA-
interruptions within the CAG-repeat. Neurodegenerative processes known as Spinocerebellar 
Ataxia type 2 (SCA2), the motor neuron degeneration Amyotrophic Lateral Sclerosis (ALS13), 
Frontotemporal dementia, Supranuclear palsy, or Levodopa-responsive Parkinsonism can be 
triggered by this mechanism (32-39). In Drosophila melanogaster flies, the Ataxin-2 orthologue 
dATX2 was shown to act as a generic modifier gene that affects multiple if not all 
neurodegenerative disorders (40). The protein interactions between ATXN2 and several other 
disease proteins of neurodegenerative disorders (41) and the similarity of atrophy patterns 
between these polyglutamine expansion diseases suggests a common molecular 
pathomechanism among these diverse neurodegenerative disorders (42).  
Interestingly, the deficiency of ATXN2 orthologues was observed to play a beneficial role 
in these neurodegenerative processes, by alleviating or postponing them in microorganism and 
animal models (35, 43). Thus, the elucidation of the molecular effects of ATXN2 deficiency and 
of the physiological roles of Ataxin-2 may help to design neuroprotective approaches that are 
novel. Hence, we chose to document the global proteomic and metabolomic profile of Atxn2-KO 
mice in crucial tissues affected by Ataxin-2 loss- and gain-of-function, the liver and the 
cerebellum, respectively. This effort may provide insights on the target molecules and pathways 
of Ataxin-2 functions.  
 
EXPERIMENTAL PROCEDURES 
Mouse Breeding and Dissection 
Animals were bred and aged in individually ventilated cages with continuous health monitoring, 
4–6 animals per cage, under a 12 h light cycle with food (Ssniff M-Z, calories from protein 36%, 
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fat 11% and carbohydrates 53%) and water provided ad libitum. Mice were housed in 
accordance with the German Animal Welfare Act, the Council Directive of 24 November 1986 
(86/609/EWG) with Annex II and the ETS123 (European Convention for the Protection of 
Vertebrate Animals) at the FELASA-certified Central Animal Facility (ZFE) of the Frankfurt 
University Medical School. All analyses were performed on male mice with a mixed C57BL/6 _ 
129/Ola background. Genotyping was performed with tail biopsies by PCR with three sets of 
primers as previously described (Lastres-Becker-I et al 2008 Hum Mol Genet). 
 
RNA Preparation and cDNA Synthesis 
After cervical dislocation, cerebellum and liver were dissected from homozygous wild-type 
(Atxn2+/+) and knock-out (Atxn2-/-) mice at 4 months (for proteomics and metabolomics) or 6 
months of age (for immunoblots). Total RNA was extracted from these tissues by 
homogenization in 1 mL of Trizol® Reagent per 50 – 100 mg of tissue using a Pellet Pestle® 
Motor tissue homogenizer (Kontes, The Glass Company). One μg total RNA was digested with 
a DNase I Amplification Grade Kit (Invitrogen, Karlsruhe) in a reaction volume of 10 μl per tube 
in order to eliminate DNA during RNA purification prior to reverse transcription (RT-PCR) 
amplification. cDNA synthesis was performed with the Fermentas Life Sciences First Strand 
cDNA Synthesis Kit as instructed in the manual. 
 
Validation of quantitative Real-Time Reverse-Transcriptase Polymerase-Chain-Reaction 
Quantitative Real-Time Reverse-Transcriptase Polymerase-Chain-Reaction (qPCR) was 
performed using a GeneAmp® 5700 Sequence Detection System (Applied Biosystems, CA 
USA) with 96-well Optical Reaction Plates (Applied Biosystems, CA USA). Twenty μl final 
reaction volume per well contained 25-30 ng cDNA, TaqMan® Universal PCR Master Mix, No 
AmpErase® UNG and primers and probes in pre-designed TaqMan® Gene Expression Assays. 
All assays were run in triplicates. The following assays were used: Atxn2 (Mm 01199894_m1) to 
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verify the KO genotype per tissue and Tbp (Mm 00446973_m1) as an endogenous control in all 
experiments, run in wells separate from the target gene assays. The PCR conditions were 
50 °C for 2 min and 95 °C for 10 min followed by 40 cycles at 95 °C for 15 seconds and 60 °C 
for 40 seconds. Analysis of relative gene expression data was performed using the ΔΔCT 
method. 
 
Metabolite Extraction for Metabolome Profiling 
Tissues were dissected, washed in phosphate buffered saline (PBS, pH7.4) and shock frozen in 
liquid nitrogen. About 40-50 mg of each liver tissue and cerebellum was used for metabolite 
profiling, six WT versus six Atxn2-KO, respectively. Cold methanol (1.5 mL, -20°C) and 0.1% 
ammonium acetate (0.2 mL) were added to the frozen tissues and subsequently homogenized 
by FastPrep (settings: 1 x 60 s; 4.5 m/s) with a steel ball. The first set of internal standards was 
added to each sample, containing chloramphenicol and C13-labeled L-glutamine, L-arginine, L-
proline, L-valine and uracil (3.5 µM final concentration). Lysates were transferred to a 15 mL 
tube, 5 mL methyl-tert-butyl ester (MTBE) was added and incubated at RT for 1 h on a rocking 
platform. Afterwards, 1.25 mL MS grade water was added and incubated for additional 10 min. 
After centrifugation at 1000 g at 4 °C for 10 min, organic and inorganic phases were separately 
transferred and combined in three tubes containing the second internal standard set (Avanti 
Polar Lipids, Alabaster, AL, USA), dedicated for subsequent analysis by using methanol, 
acetonitrile, and water as alternative solvents for LC-MS runs. Metabolites were lyophilized and 
stored at -80 °C until needed. The residuals were suspended in 50 µL of ACN with 0.1% FA and 
35 µL of MeOH with 0.1% FA for analysis by HILIC and in 50 µL of H2O with 0.1% FA for RPLC 
and were then sonicated for re-dissolving as needed and centrifuged at 17500 g for 5 min at 
4 °C. The supernatants were transferred to microvolume inserts, and 5 µl per run was injected 
for LC-MS/MS analysis.  
 
 8
LC Conditions for Metabolomics 
The target metabolites were selected to cover most of the important metabolic pathways in 
mammals, more than 400 metabolites in total. The chromatographic separations were 
performed on RP, RP-shield and zicHILIC stationary phases. Following columns were used: 
Reprosil-PUR C18-AQ (1.9 µm, 120 Å, 150 x 2 mm ID; Dr. Maisch; Ammerbuch, Germany) 
column, BEH Shield RP18 (1.7 µm, 130 Å, 150 x 2.1 mm ID; Waters; Milford, MA) and a 
zicHILIC (3.5 µm, 100 Å, 150 x 2.1 mm ID; di2chrom; Marl, Germany) A 1290 series UHPLC 
(Agilent, Santa Clara, CA, USA) with six different buffer conditions was used: (A1) 10 mM 
ammonium acetate in LC-MS grade H2O (adjusted with FA to pH 3.5), (A2) 10 mM ammonium 
acetate in LC-MS grade H2O (adjusted with ammonium hydroxide to pH 7.5), (A3) 20 mM 
ammonium formate in LC-MS grade H2O (adjusted with ammonium hydroxide to pH 5.0), (B1) 
LC-MS grade ACN with 0.1% FA, (B3) LC-MS grade MeOH; B2: LC-MS grade MeOH with 0.1% 
FA. Gradients and flow conditions are described in supplemental Table S1. Columns were run 
under controlled temperature of 30 °C, RP-shield with 80 °C. The columns were equilibrated 
with a blank run in the corresponding buffer system. 
The LC was online coupled to a triple quadrupole hybrid ion trap mass spectrometer QTrap 
6500 (ABSciex, Toronto, Canada). MS settings were reported previously (44), transition settings 
for the MRM’s in supplemental Table S2. 
 
Metabolome Data Analysis 
Relative quantification was performed using MultiQuant software v.2.1.1 (AB Sciex, Foster City, 
CA, USA), as described previously (44). Briefly, the identification of metabolites was based on 
the retention time, three co-occurring transitions and the ion ratio between the transitions, which 
had to match to MRM ion ratios of the corresponding tuned metabolites. Biological replicates 
were normalized for the weighted mg of tissue and internal standards. 
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Sample Preparation for Proteome Profiling 
The same tissues were used as for metabolome profiling. About 10 mg of liver tissue and 
cerebellum was weighted under frozen condition. Samples were lysed and reduced in buffer 
containing 8% SDS, 0.1 M DTT, 0.1 M Tris, pH 8 and subsequently homogenized by FastPrep 
(settings: 3 x 60 s; 4 m/s) with a steel ball. Lysates were sonicated on ice for 1 min and boiled at 
95 °C for 5 min at a rocking platform (750 rpm). Samples were prepared for LC-MS analysis as 
previously (44). In brief, lysates were centrifuged for 5 min at 15.000 g, supernatants were 
reduced in 50 mM DTT for 1 h at 56 °C. Alkylation was done with a final concentration of 
5.5 mM chloroacetamide for 30 min at RT in the dark. Samples were precipitated with 4-times 
excess of acetone overnight at -20 °C. Precipitates were lyophilized and dissolved in 8 M 
urea/10 mM Tris pH 8. Lys-C digestion (1 µg/sample) was performed for 4 h at room 
temperature followed by a trypsin digestion (2 µg/sample) in 2 M urea overnight at 37 °C. 
Peptides were purified with C18 columns (Sep-Pak® Vac, 100mg, Waters, Milford, MA). 1% of 
the total peptides were finally injected and analyzed by liquid chromatography online coupled to 
a nanoHPLC-MS/MS system, after dissolving in 5% ACN and 2% FA. Every sample was run as 
a technical replicate. 
 
LC-MS Settings for Proteomics 
LC−MS/MS was carried out by nanoflow reverse phase liquid chromatography (Dionex Ultimate 
3000, Thermo Scientific, Waltham, MA) coupled online to a Q-Exactive Plus Orbitrap mass 
spectrometer (Thermo Scientific, Waltham, MA). Briefly, the LC separation was performed using 
a PicoFrit analytical column (75 μm ID × 25 cm long, 15 µm Tip ID (New Objectives, Woburn, 
MA) in-house packed with 3 µm C18 resin (Reprosil-AQ Pur, Dr. Maisch, Ammerbuch-
Entringen, Germany). Peptides were eluted using a non-linear gradient from 2 to 40% solvent B 
over 210 min at a flow rate of 266 nL/min (solvent A: 99.9% H2O, 0.1% formic acid; solvent B: 
79.9% acetonitrile, 20% H2O, 0.1% formic acid). 3 kV were applied for nanoelectrospray 
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generation. A cycle of one full FT scan mass spectrum (300−1750 m/z, resolution of 70,000 at 
m/z 200, AGC target 1e6) was followed by 12 data-dependent MS/MS scans (resolution of 
35,000, AGC target 5e5) with normalized collision energy of 25 eV. In order to avoid repeated 
sequencing of the same peptides, a dynamic exclusion window of 30 sec was used and only the 
peptide charge states between two to eight were allowed. 
 
Label Free Proteomics Data Analysis 
Raw MS data were processed with MaxQuant software (v1.5.0.0) (45) and searched against the 
Mus musculus (MOUSE) proteome database UniProtKB with 52.490 entries, released in 2014-
11, respectively. Additionally, the “re-quantify” feature was implemented to increase the number 
of peptides which can be used for quantification. LC-MS runs of technical replicates were jointly 
analyzed. A false discovery rate (FDR) of 0.01 for proteins and peptides and a minimum peptide 
length of 7 amino acids, a mass tolerance of 4.5 ppm for precursor and 20 ppm for fragment 
ions were required. A minimum Andromeda score of 0 and 40 (delta score 0 and 9) for 
unmodified peptides and modified peptides was applied. A maximum of two missed cleavages 
was allowed for the tryptic digest. Cysteine carbamidomethylation was set as fixed modification, 
whereas N-terminal protein acetylation and methionine oxidation were set as variable 
modifications.  
The LFQ, a generic method for label-free quantification (46) within MaxQuant, was used for 
relative quantification. MaxQuant processed output files can be found in supplemental Tables 
S3-S4, showing peptide and protein identification, accession numbers, % sequence coverage of 
the protein, posterior error probability (PEP) values, log2 transformed LFQ intensities and fold 
changes between KO/WT. Contaminants as well as proteins identified by site modification and 
proteins derived from the reversed part of the decoy database were strictly excluded from 
further analysis. The mass spectrometry proteomics data have been deposited to the 
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ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE 
partner repository (47) with the dataset identifier PXD003155. 
 
Statistical, Pathway, and PPI Network Analyses 
Pathway and network analyses are novel methods to understand the complex data sets derived 
from deep omics studies. For the metabolome and proteome data, a two-sample t-test was 
performed within Perseus software (v1.5.0.8, (45). Multiple test correction by Benjamini-
Hochberg (BH) with a FDR of 0.05 was performed after the p-value calculation. Significantly 
regulated metabolites and proteins were marked by an asterisk in the corresponding 
supplemental tables S3-S4. Furthermore, volcano plots and Pearson correlation were created 
within Perseus. Only proteins with valid values in all replicates were used for the above 
mentioned tests.  
For comprehensive proteome data analyses, gene set enrichment analysis (GSEA, v2.2.0) (48) 
was applied in order to see, if a priori defined sets of proteins show statistically significant, 
concordant differences between KO and WT state. Only proteins with at least two valid values in 
each cohort were used for GSEA analysis and the ratios were log2 transformed. GSEA default 
settings were used, except that the minimum size exclusion was set to 5 and KEGG v5.0 was 
used as gene set database. The cutoff for significantly regulated pathways was set to ≤ 0.05 p-
value and ≤ 0.05 FDR. 
For protein-protein interaction (PPI) network analyses, the software tool String v.10 was used to 
visualize networks of significantly regulated proteins of the entire proteome with a confidence 
level of 0.7 (49). The cutoff for significantly regulated proteins was determined using one 
standard deviation from the log2 transformed median by using GraphPad Prism 5.03. Protein 
nodes which were not integrated into a network were removed. 
 
Quantitative Immunoblot Analyses 
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The isolation of total proteins from liver of 7 wild-type and 7 Atxn2-KO mice at the age of 
6 months was performed as described (50) with minor modifications: Prior to gel 
electrophoresis, 20μg samples were heated at 90°C for 2 min, using Precision Plus Protein™ 
Dual Color Standards as size marker. Transfer to nitrocellulose membranes (Protran, GE 
Healthcare) was done at 50 V for 90 min, with blocking in 5% BSA solution in 1X TBS-T for 1 h 
at room temperature (RT). Primary antibodies against β-Actin (1:5000, A5441, Sigma-Aldrich), 
ACADS (1:500, ab154823, Abcam), ALDH6A1 (PA5-34691, Thermo Fischer), ALDH7A1 (PA5-
29974, Thermo Fischer), IVD (1:250, PA5-22342, Thermo Fischer), MCCC2 (PA5-27758, 
Thermo Fischer), OTC (1:500, PA5-28197, Thermo Fischer), and PCCA (1:250, ABIN518660, 
MaxPab®) in 5% BSA solutions initially for 1 h at RT, and then overnight at 4 °C. Fluorescent-
labelled α-mouse (1:15.000, IRDye 800CW, Li-Cor) and α-rabbit (1:15.000, IRDye 680RD, Li-
Cor) were the secondary antibodies. Fluorescence detection occurred on the Li-Cor Odyssey 
Classic Instrument. Statistical significance was assessed using unpaired t-test with Welch’s 
correction.  
RESULTS 
Proteomic Profiling  
In order to determine the molecular effects of the Atxn2-KO in 4-month-old mouse liver 
and cerebellar tissue, we first performed global proteome quantifications by label-free mass 
spectrometry. Atxn2-KO was verified by genotyping of tail biopsies at the DNA level as 
previously described (30) and verified in the tissues under study by real-time qPCR at the 
mRNA level. Additionally, we looked at the proteome level for the evidence of ATXN2 presence 
in all samples, and observed six different ATXN2 specific peptides exclusively in wild-type (WT) 
samples, never in KO samples (data not shown).  
Comparison of the proteome profiles of all six biological replicates of WT and Atxn2-KO 
mice was done by Pearson correlation. The Pearson correlation coefficients were highly similar, 
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ranging from 0.766 to 0.981 in WT and KO liver tissue (supplemental Fig. S1), and from 0.928 
to 0.992 in WT and KO cerebellar tissue (supplemental Fig. S2). These Pearson correlation 
coefficients suggested a very good quality of the proteome data sets. 
The entire list of identified and quantified protein groups can be found in supplemental 
Tables S3 and S4 for liver and cerebellar tissue, respectively. This resulted in 823 protein 
groups in liver versus 999 protein groups in cerebellar tissue, respectively. For pathway- and 
PPI network analyses, we accepted at least 2 valid values per sample cohort, resulting in 1609 
protein groups in liver versus 1982 protein group ratios in cerebellar tissue, respectively.  
 
Proteomic Profiling in Liver Tissue 
To identify significantly (after BH correction) regulated protein groups, the distribution 
between KO and WT cohorts was visualized in a volcano plot (Fig. 1).  
The significantly dysregulated proteins were detailed in Table 1. PCCA, ALDH6A1, IVD 
and MCCC2 are involved in the valine, leucine and isoleucine (branched chain amino acids, 
BCAA) degradation pathway. OTC is part of the arginine biosynthesis pathway, synthesizing L-
citrulline from L-ornithine. ALDH7A1 is a key enzyme in the pathways lysine biosynthesis / 
lysine degradation and ACADS is involved in the pathway mitochondrial fatty acid beta-
oxidation. 
To illustrate the relative protein abundance and the variability of measurements as criteria for 
their relevance, the LFQ ion intensity distributions of every single individual mouse tissue was 
shown for the 7 significant proteins (Fig. 2).  
Applying the STRING software, we visualized the network of molecular interactions 
among downregulated proteins (at least 1 standard deviation from the mean) in Atxn2-KO/WT 
liver tissue (Fig. 3). The most striking pathway within this network was again the BCAA 
metabolism. Furthermore, protein-protein interaction networks involved in the ribosome and 
 14
cytochrome P450 metabolism, fatty acid metabolism and several amino acid metabolisms were 
downregulated as well (smaller networks in Fig. 3). 
Even more sophisticated ways to analyze the entire proteomics dataset, taking all ratios 
into account without any ratio cutoffs, are assessment methods of pathway enrichment such as 
GSEA (Gene Set Enrichment Analysis). For liver tissue, no significantly upregulated KEGG 
pathway was identified with this approach, but several significantly downregulated KEGG 
pathways were identified. Most striking was the downregulation of the pathway branched chain 
amino acids (BCAA, that is leucine, isoleucine and valine) and several related amino acid 
metabolism pathways. Furthermore, the pathways fatty acid metabolism and the citric acid cycle 
(tricarboxylic acid or TCA cycle) were significantly downregulated (Table 2, supplemental Table 
S5).  
 
Proteomic Profiling in Cerebellar Tissue 
For cerebellar tissue, we used identical approaches for data analysis as for liver tissue. 
On the protein level, no significantly regulated proteins were identified after BH correction 
(supplemental Table S4, volcano plot in supplemental Fig. S3). Compared to the PPI network 
generated for liver tissues, the BCAA pathway could still be identified as a network by applying 
at least one standard deviation (cerebellum 0.06144 ± 0.3175) of down regulated proteins, but 
to a much lesser degree (supplemental Fig. S4).  
GSEA analyses revealed a nominal significance for upregulations of KEGG pathways 
proteasome, purine metabolism, amyotrophic lateral sclerosis and VEGF signaling 
(supplemental Table S5), and nominal significance for downregulations of pathways ribosomes 
and valine, leucine & isoleucine degradation again. In general, the fold changes in cerebellum 
were rather small.  
 
Metabolomic Profiling  
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We applied a targeted LC-MS/MS methodology, based on multiple reaction monitoring 
(MRM) to identify and quantify relative differences in metabolite changes of selected metabolites 
between Atxn2-KO and WT mice in liver and cerebellar tissue. The correct retention time, three 
MRM’s and a matching MRM ion ratio of tuned pure metabolites as a reference were used for 
correct identification of metabolites (44). In total, 176 metabolites could be identified and 
relatively quantified in liver tissue, 204 in cerebellum. The entire lists of all quantified metabolites 
can be found in supplemental Table S6.  
Comparison of the metabolome profiles of all six biological replicates of WT and Atxn2-KO mice 
was done by Pearson correlation. The Pearson correlation coefficients were highly similar, 
ranging from 0.803 to 0.994 in KO and WT liver tissue (supplemental Fig. S5). In cerebellum, 
the range was from 0.83 to 0.985 (supplemental Fig. S6). These Pearson correlation 
coefficients suggested a very good quality of the metabolome data sets. Statistical analyses by 
a two sample t-test with BH correction was visualized by volcano plots and revealed no 
significantly regulated metabolites (supplemental Fig. S7-8), the fold ratios were too small in 
comparison to the variability.  
 
Proteome- Metabolome Integration 
Nevertheless, the fold-changes in the metabolome data fitted the proteome profile closely.  
Within mitochondria, PCCA and PCCB control the conversion between propionyl-CoA and 
methyl-malonyl-CoA, MLYCD converts malonyl-CoA to acetyl-CoA in the ß-alanine metabolism. 
Propionyl-CoA and malonyl-CoA are conjugated to carnitine for elimination from mitochondria. 
Carnitine O-palmitoyltransferase 1 (liver isoform) and 2 (CPT1A, CTP2), catalyzing the transfer 
of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the 
mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the 
mitochondrion, were 1.5- and 2.3- fold down regulated in Atxn2- KO liver tissue, respectively. 
Interestingly, acylcarnitines, such as propionylcarnitine, malonylcarnitine and pimelylcarnitine 
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were 2- to 2.5-fold increased. Malonylcarnitine is known to accumulate with specific disruption of 
fatty-acid oxidation caused by impaired entry of long-chain acylcarnitine esters into the 
mitochondria and failure of the mitochondrial respiratory chain (51). Furthermore, medium-chain 
acyl-CoA dehydrogenase deficiency is caused by mutation in the medium-chain acyl-CoA 
dehydrogenase gene (ACADM) (52), which was 2-fold decreased in Atxn2-KO liver tissue. 
The previously reported accumulation of fat droplets in Atxn2-KO liver (30) is in excellent 
agreement with these metabolomics findings and with the proteomic observation of 
downregulated ACADS, which catalyzes the initial step of the mitochondrial fatty acid beta-
oxidation. Furthermore, one of the strongest downregulations in the metabolomics profile of 
Atxn2-KO liver was for biotin (0.54-fold), an important cofactor for the BCAA pathway enzymes. 
The interplay of the key findings in Atxn2-KO liver were displayed in an integrative “omics” figure 
(Fig. 4).  
 
Candidate Protein Validation in Liver Tissue  
So as to assess the main proteomics findings by an independent technique, RIPA-buffer 
extracted proteins from liver tissue of Atxn2-KO/WT mice at age 6 months were analyzed in 
quantitative immunoblots with commercially available antibodies (supplemental Fig. S9). A 
reduced abundance was confirmed for IVD (change to 0,06-fold ± 0,03, p=0,0038), PCCA (to 
0,25-fold ± 0,02, p< 0,0001), ACADS (to 0,16-fold ± 0,018, p<0,0016), OTC (to 0,58-fold ± 0,03, 
p<0,0042), ALDH6A1 (to 0,67-fold ± 0,03, p=0.0006) and MCCC2 (to 0,44-fold ± 0,04, 
p<0.0001). These studies confirm the mass spectrometry data on altered BCAA and fatty acid 
metabolism and should facilitate future mechanistic investigations in vitro. 
DISCUSSION 
Our global proteome quantification and biomathematical enrichment analysis by GSEA 
documented several significant effects. Less impressively, the metabolomics quantification 
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showed several changes above 2-fold, but none of them was significant and sophisticated 
pathway enrichment software tools such as GSEA are unavailable for metabolome data. The 
proteome showed strong downregulations of the KEGG pathways for branched chain amino 
acid (BCAA) metabolism, fatty acid metabolisms and citric acid cycle in liver, an observation that 
was supported with nominal significance and smaller fold-changes in cerebellar tissue for the 
BCAA pathway. Of course, fluctuations in food intake and exercise or stress perturb the leucine 
homeostasis and trophic signaling. Since our analyses started without prior hypothesis, we used 
animals that had been fed at libitum and had been allowed to move freely or fight among 
several siblings per cage, without any standardization effort such as overnight fasting and 
individual cages. Thus, it is understandable that considerable variance was encountered for the 
short-lived compounds in the metabolomic survey, while the variance was milder for the long-
lived proteins. The variance reduced the significance levels of our metabolomics findings, but 
the fold-changes of acylcarnitines and biotin should still be taken into account, given that it is 
well established that acylcarnitines will vary with food intake and exercise and stress (53). 
Biological systems are always balancing their homeostasis and compensating small anomalies, 
obscuring minor metabolic effects of the Atxn2 gene. That might be one reason, why the citrate 
cycle appeared unchanged at the metabolome level while it was detectable as pathway 
enrichment of minor effects in the proteome. Furthermore, many metabolites from different 
pathways are joining or exiting the citrate cycle at different points that can flatten out Atxn2-KO 
specific effects.  
In the proteomics survey, the significant downregulations of the individual proteins 
ACADS (involved in mitochondrial fatty acid beta-oxidation), ALDH6A1 (involved in 
mitochondrial valine and pyrimidine catabolism via malonate-methylmalonate decarboxylation to 
acetyl/propionyl-CoA), ALDH7A1 (involved in mitochondrial lysine catabolism and stress-
protection by metabolizing lipid peroxidation-derived aldehydes), IVD (involved in mitochondrial 
leucine catabolism), MCCC2 (involved in mitochondrial leucine and isovaleric acid catabolism), 
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PCCA (involved in mitochondrial valine/leucine/isoleucine catabolism and lipid degradation) and 
OTC (involved in mitochondrial glutamate degradation) converge to impair the degradation of 
amino acids and fatty acids while altering the generation of methyl-malonyl-CoA, propionyl-CoA 
and malonyl-CoA (Fig. 4). The usage of malonyl-CoA can switch from (1) serving as building 
block for the biosynthesis of larger fatty acids in a process that is insulin-dependent, via (2) 
regulating fatty acid oxidation and neuroprotective ketogenesis with glycogen breakdown in the 
liver during starvation periods, to (3) the conversion to acetyl-CoA as a substrate for the TCA 
cycle (54). A technically independent confirmation of these data, with commercially available 
antibodies being used in quantitative immunoblots, indicated that the strongest effect reduces 
the levels of IVD to less than 10% and suggests that leucine catabolism should be particularly 
affected. 
Thus, our proteomic findings correspond well to the previous documentation of chronic 
accumulation of lipid droplets and glycogen in the liver of Atxn2-KO mice (30). It is known that 
elevated blood plasma levels of BCAAs serve as markers of obesity, insulin resistance and 
diabetes mellitus (55), so they are key indicators of metabolic excess. Conversely, depleted 
plasma levels of BCAA serve as biomarkers of the polyQ-expansion triggered 
neurodegenerative process and weight loss in Huntington’s disease (56, 57). Thus, it will be 
interesting to test whether depleted plasma levels of BCAA are also associated with the neural 
atrophy caused by the polyQ-expansion of ATXN2 in SCA2 and ALS13. It is well established 
now that polyQ-expansions trigger an aggregation process, which is toxic through oligomer 
formation, but also through the longer half-life (35) of the disease protein with a gain in 
physiological functions. This process also sequestrates interaction molecules into insolubility 
leading to partial losses of physiological functions (8). Thus, polyQ-expanded proteins contribute 
to pathogenesis in the context of their cellular function (58-63). Not only polyQ-expansions in 
ATXN2, but also other variants in the ATXN2 gene are associated with ALS risk, presumably via 
altered physiological functions (37). Furthermore, the aggregation process of SCA2 is less 
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conspicuous in cerebellar neurons than in motor neurons, in spite of cerebellar vulnerability to 
SCA2 (64, 65). Therefore, our understanding of the role of ATXN2 in metabolic excess 
syndromes and neural atrophies may be furthered by the identification of downstream effects 
such as BCAA metabolism. 
The accumulation of the Ataxin-2 protein in neurons is thought to occur in insidious 
manner over decades, so the resulting neurotoxicity develops slowly and does not manifest until 
reaching a threshold at advanced ages. For this reason, apparently insignificant 2-fold changes 
in metabolites such as the BCAA pathway intermediates might have cumulative neurotoxic 
effects across the human lifespan. This is relevant, because strongly deficient degradation of 
BCAA is well known to result in childhood-onset diseases summarized under the term 
branched-chain organic acidurias, comprising maple syrup urine disease, isovaleric aciduria, 
propionic aciduria and methylmalonic aciduria, which frequently have delayed 
neurodevelopmental stages or neurodegenerative processes (66). Of therapeutic value may be 
the observation that dietary restriction of BCAAs may mitigate some neurological complaints 
(67). Similarly, the twofold reduction in biotin in the metabolomics survey might be relevant, in 
spite of apparently being insignificant. Biotin levels are mostly derived from protein degradation 
in food uptake and thus vary considerably in animals fed ad libitum. Biotin is relevant as an 
essential factor for amino acid metabolism, gluconeogenesis and fatty acid metabolism. 
Biotinidase (BTD) deficiency leads to ataxia and paresis, a biotin supplementation is used to 
normalize leucine and isoleucine metabolism, and a biotinidase knockout mouse activates AMP 
Kinase while inhibiting mTOR signaling (68). To obtain normal biotin levels from dietary protein, 
not only biotinidase is necessary, but also the transporters monocarboxylate transporter 1 
(SLC16A1) and sodium-dependent multivitamin transporter (SLC5A6) as well as the protein 
ligase holocarboxylase synthetase (HLCS), see Fig. 4 (69). Thus, a mild reduction in biotin 
levels in cumulative manner might contribute to pathogenesis. 
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It is also noteworthy that the availability of branched chain amino acids such as leucine 
is a strong stimulus for mTORC1 signaling and the initiation or mRNA translation and protein 
biosynthesis, while uncoupling the insulin signals (55, 70-72). The mTOR phosphorylation 
pathway directly governs the transcription of ERRalpha-target genes involved in energy 
metabolism including lipogenesis and citric acid cycle (71). Indeed, ATXN2 was found to 
modulate the leucine / mTOR-driven phosphorylation of ribosomal protein S6 and also the 
incorporation rate of radioactive amino acids during mRNA translation (4). Therefore, the 
impairment of BCAA metabolism may be a direct marker of putative effects of ATXN2 deficiency 
on mTORC1 signaling. Recently, the yeast orthologue of ATXN2, PBP1, was shown to 
sequestrate yeast TORC1 to stress granules in times of low cellular energy in a process that is 
regulated through phosphorylation signals by SNF1 - the yeast orthologue of human AMPK1 - 
and PAS kinase (73-75). According to this scenario, deficient TORC1 sequestration in the 
absence of ATXN2/PBP1 would result in unhampered cell growth even in periods of low 
nutrients and energy, while overactive TORC1 sequestration due to gain-of-function mutations 
of ATXN2/PBP1 such as polyQ expansions would result in cellular atrophy in spite of abundant 
nutrients and energy. Thus, the observations of downregulated BCAA, fatty acid and citric acid 
cycle pathways in our global proteome profiling are credible in view of previous reports on 
ATXN2 orthologues and on the pathomechanism of obesity versus polyQ-triggered 
neurodegenerative diseases. 
It is interesting to note that a recent report identifies the branched-chain amino acid 
catabolism to be a conserved regulator of physiological aging (76), while age is of course the 
best-established risk factor for the manifestation of many human diseases such as obesity and 
neurodegeneration. 
Overall, the global proteome and metabolome profiling of Atxn2-KO mouse liver and 
cerebellum indicates that ATXN2 modulates nutrition and basal metabolism. The deficient or 
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Fig. 1.  Volcano plot featuring liver proteome data, with the mean difference of LFQ 
intensities between Atxn2 KO and WT tissues on the x-axis versus statistical significance 
on the y-axis (-log10 of the p-value). Significant regulated proteins are identified in red. 
 
Fig. 2.  Log2 LFQ ion intensities of all six biological replicates in Atxn2-KO/WT liver 
tissues are shown. Red = KO; blue = WT. Error bars are mean values with SD.  
 
Fig. 3. STRING PPI network and pathway analysis of proteins with downregulation at 
least one standard deviations from the log2 transformed median values (0.03227 ± 0.4819) 
in Atxn2-KO/WT liver tissue. Highlighted in red are proteins which belong to the KEGG 
pathway BCAA. Unconnected nodes were removed.  
 
Fig. 4. Metabolomics and proteomics overview of the impact of an Atxn2-KO in liver 





Table 1: List of significant altered proteins in KO/WT liver tissue. Posterior error probability 
(PEP), MS2 spectral count frequency (MS/MS Count), Benjamini-Hochberg corrected p-values 




















mitochondrial Ivd + 0 363 4,0434 0.48 
Alpha-aminoadipic semialdehyde 
dehydrogenase Aldh7a1 + 0 642 3,9197 0.67 
Short-chain specific acyl-CoA 
dehydrogenase, mitochondrial Acads + 0 480 3,7971 0.57 
Ornithine carbamoyltransferase, 
mitochondrial Otc + 0 1476 3,6804 0.61 
Methylcrotonoyl-CoA carboxylase 
beta chain, mitochondrial Mccc2 + 0 308 3,6148 0.61 
Methylmalonate-semialdehyde 
dehydrogenase [acylating], 
mitochondrial Aldh6a1 + 0 1085 3,4525 0.73 
 
 
Table 2. Significantly (p-value and q-value ≤0.05) downregulated KEGG pathways in KO/WT 
liver tissue according to GSEA. Size, number of identified proteins within the pathway; NES, 
normalized enrichment score.    
KEGG pathway SIZE NES NOM p-value FDR q-value 
Valine leucine and isoleucine degradation 36 -2.69 0 0 
Propanoate metabolism 25 -2.36 0 0 
Fatty acid metabolism 25 -2.31 0 0 
Glycine serine and threonine metabolism 21 -2.28 0 0 
Butanoate metabolism 24 -2.17 0 0 
Citric cycle TCA cycle 23 -2.07 0.0024 0.0014 
Beta alanine metabolism 16 -1.98 0 0.0041 
Alanine aspartate and glutamate metabolism 19 -1.88 0 0.0152 
Arginine and proline metabolism 27 -1.85 0.0022 0.0197 
Lysine degradation 18 -1.84 0.0044 0.0201 
Tryptophan metabolism 25 -1.79 0.0023 0.0294 
Limonene and pinene degradation 8 -1.76 0.0177 0.0389 
Pyruvate metabolism 24 -1.73 0.0024 0.0452 
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